Baudax Bio Inc · OTC:BXRXQ
Baudax Bio — Corporate Update (October 2023)
17 slides from Baudax Bio's corporate update, Oct 6, 2023
Slide 1: October 2023
| 99.1 4 October 2023 #Teralmmune sBauDax BIO
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opport
Slide 3: Highlights
Highlights Baudax Bio: Development and Commercialization Teraimmune: Discovery Platform and Research IND cleared for TCR Treg, expected “once and done” treatment to eradicate “inhibitors/auto-antibodies” interfering with Factor VIII therapy for Hemophilia A. Q1 ‘24 target for first ever human TCR Tr
Slide 4: Senior Leadership Team
Senior Leadership Team Gerri Henwood - President & CEO Founder, President, CEO Baudax, Recro President of Malvern Consulting Group Founder, Pres., CEO Auxilium (NASDAQ: AUXL) Founder, CEO IBAH (NASDAQ: CRO) >10 years at SK&F (now GSK) Stewart Mc Callum, MD - Consulting CMO EVP Medical Affairs, Bauda
Slide 5: What is the opportunity?
What is the opportunity? Expected Q1 ‘24 open and begin enrollment of Phase 1/2a TI 168 trial in Hemophilia A patients with inhibitors. Clinical trial for an orphan drug complication. Treatment expected to be “once and done” administration of patient’s own targeted Tregs (modified to block productio
Slide 6: Hemophilia A with Inhibitors
Hemophilia A with Inhibitors Estimated 180,000 Hemophilia A patients in the developed world Hemophilia A patients do not make Factor VIII, needed for normal blood clotting About 30% of the Hemophilia A patients develop antibodies to Factor VIII, called inhibitors that make it hard to use Factor VIII
Slide 7: Proprietary First-In-Class Platform for Manufacturing TCR Tregs
Proprietary First-In-Class Platform for Manufacturing TCR Tregs These unique TCR Tregs are intended to act to clear pathologic autoantibodies by inducing tolerance to a specific protein without systemic immune suppression (does not reduce systemic IgG) 1 Immune cell collection 2 Treg isolation 3 Vir
Slide 8: TCR Treg Mechanism of Action in Autoimmune Disease
TCR Treg Mechanism of Action in Autoimmune Disease Autoimmune Disease Treatment with TCR Tregs TCR Tregs block pathologic Autoantigen- specific B cells activation and differentiation Antigen recognition induces expression of effector T cells, activating B cells B cells proliferate and differentiate
Slide 9: FVIII TCR Tregs preclinical efficacy in hemophilic mice
Non-specific TCR Tregs FVIII TCR Tregs FVIII CAR Tregs Hemophilic mice were subcutaneously immunized with FVIII on day 0 4h after immunization, mice were infused with Control, TCR Tregs or CAR Tregs FVIII –specific antibody levels were monitored weekly, and mice rechallenged with FVIII on day 56 * H
Slide 10: TCR Treg Program TI-168
TCR Treg Program TI-168 IND with associated preclinical and manufacturing data as well as clinical study protocol have been cleared. Initiating clinical study process Study site selection (specially qualified sites) IRB approval process – at specialized sites can be extended, but we believe 1 or mor
Slide 11: Research Program Priorities
Research Program Priorities Develop AChR* TCR Treg Verify the TCR as appropriate for the target Preclinical model development and qualification of proposed TCR Treg CMC and preclinical model studies preparatory work for IND IND filing target : 2025 * Acetylcholine receptor (AChR) Myasthenia Gravis (
Slide 12: Strong Interest in Treg Cell Therapies
Strong Interest in Treg Cell Therapies Companies 2021 2022 Acquired by Merck for $1.85B Phase I Ulcerative Colitis $84M on Series A Preclinical Liver Transplantation $95M on Series A Preclinical MS, TTD $85M on Series A Preclinical Autoimmune $157M on Series A Preclinical T1D $265M on Series B Precl
Slide 13: NMB Portfolio
NMB Portfolio
Slide 14: NMB – Anesthesia Pipeline
NMB – Anesthesia Pipeline Continue at modest, sustainable pace Pre-clinical Phase 1 Phase 2 Phase 3 Milestones NEUROMUSCULAR BLOCKING AGENTS (NMBs) IV Intermediate-action (BX1000) Top-line data reported/Q2 2023 IV Ultra-short action (BX2000) Last patient dosed/end ‘24 NMB REVERSAL (ANESTHESIA) BX300
Slide 15: Baudax Bio Recent Financing
Baudax Bio Recent Financing Gross Proceeds from December 2022 Public Offering Raised in early January 2023 through warrant exercise $5 Million $4.3 Million Gross Proceeds from May 2023 Public Offering $4 Million Raised in August 2023 through additional financing $1.9 Million
Slide 16: Highlights
Highlights Baudax Bio: Development and Commercialization Teraimmune: Discovery Platform and Research IND cleared for TCR Treg, expected “once and done” treatment to eradicate “inhibitors/auto-antibodies” interfering with Factor VIII therapy for Hemophilia A. Q1 ‘24 target for first ever human TCR Tr
Slide 17: Contact Information
Contact Information Mike Moyer LifeSci Advisors mmoyer@lifesciadvisors.com